Your Search Results

TAVI procedural complications - Part 6: paravalvular leak, basilica and more

20 May 2026 – From EuroPCR 2026

Delve into complex TAVI procedural complications including paravalvular leak and challenges such as BASILICA technique failures, aortic dissection, valve infolding, and valve dislocation. This session presents real-world cases illustrating troubleshooting strategies and innovative interventions like TAVI-in-TAVI procedures to address these critical scenarios.

Intracoronary imaging insights in ACS

20 May 2026 – From EuroPCR 2026

Discover how intracoronary imaging advances understanding and management of acute coronary syndromes (ACS). This session explores high-definition intravascular ultrasound for PCI guidance, novel predictive metrics, and the impact of emerging factors like microplastics on plaque instability, alongside pathophysiological insights into layered plaques and coronary ectasia in...

Innovation in transcatheter mitral valve interventions

21 May 2026 – From EuroPCR 2026

This comprehensive session presents the latest innovations in transcatheter mitral valve interventions, highlighting cutting-edge devices and clinical experiences. Topics include early feasibility studies of novel hemivalve systems, first-in-human experiences with new mitral valve replacement technologies, advances in transcatheter edge-to-edge repair (TEER) with one-year outcome data, and...

Complex PCI - Best cases from PCR Global Interventional Academy - Part 2

21 May 2026 – From EuroPCR 2026

This session showcases best cases from the PCR Global Interventional Academy focusing on complex PCI scenarios. It addresses challenges such as managing ostial left anterior descending artery lesions, strategies for branch protection, implications of coronary involvement during TAVI, and future directions in complex coronary interventions. The...

5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)

01 Apr 2025

Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.